FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease

Published on May 12, 2023
Today, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved treatment option for this indication.
Continue reading on website
Other news

Leading through learning — Taking the Hire Road

May 12, 2023
This week on Taking the Hire Road, Jeremy Reymer, founder and CEO of DriverReach, is joined by passionate and engaging next-generation executive Ashley Kordish, CEO of Michigan-based Ralph Moyle Inc. (RMI).Recently highlighted in an issue of TSA’s Truckload Authority, Kordish was born and raised in the logistics industry: RMI was founded by her grandfather in 1966. “When I say I grew up in the ind

Wacker Purchases ADL BioPharma

May 12, 2023
Wacker’s chemical group reported that it has acquired 100 percent of the shares of ADL BioPharma, a CMO. The shares were purchased from Kartesia, a financial investor with whom Wacker signed a corresponding agreement finalizing the transaction last week. Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site, wit